Overall responses and survival in RCC on pegilodecakin with anti-PD-1

被引：0
|
作者：
Naing, A. [1 ]
Infante, J. R. [2 ]
Wong, D. J. [3 ]
Korn, W. M. [4 ]
Aljumaily, R. [5 ]
Papadopoulos, K. P. [6 ]
Autio, K. A. [7 ]
Pant, S. [1 ]
Bauer, T. M. [2 ]
Drakaki, A. [3 ]
Daver, N. G. [1 ]
Hung, A. [8 ]
Verma, R. [8 ]
Ratti, N. [8 ]
McCauley, S. [8 ]
Van Vlasselaer, P. [8 ]
Tannir, M. [1 ]
Oft, M. [8 ]
机构：
[1] MDACC, Houston, TX USA
[2] SCRI, Nashville, TN USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] OUHSC, Oklahoma City, OK USA
[6] START, San Antonio, TX USA
[7] MSKCC, New York, CA USA
[8] ARMO LILLY Redwood City, Redwood City, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2019年 / 110卷
关键词：
D O I：
10.1016/j.ejca.2019.01.025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O2
引用
收藏
页码：S1 / S2
页数：2
相关论文
共 50 条
  • [1] Responses and Durability in NSCLC Treated With Pegilodecakin and Anti-PD-1
    Garon, E.
    Wong, D.
    Schneider, J.
    Aliumaily, R.
    Korn, W.
    Infante, J.
    Patel, M.
    Autio, K.
    Papadopoulos, K.
    Naing, A.
    Gabrail, N.
    Munster, P.
    Goldman, J.
    Hung, A.
    Van Vlasselaer, P.
    Leveque, J.
    Oft, M.
    Spigel, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S366 - S367
  • [2] PEGILODECAKIN PLUS ANTI-PD-1 IS TOLERABLE AND EFFECTIVE
    不详
    [J]. CANCER DISCOVERY, 2019, 9 (11) : 1482 - 1482
  • [3] Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors
    Tannir, N. M.
    Naing, A.
    Papadopoulos, K. P.
    Wong, D. J.
    Korn, W. M.
    Aljumaily, R.
    Autio, K. A.
    Pant, S.
    Bauer, T. M.
    Drakaki, A.
    Daver, N.
    Hung, A.
    Oft, M.
    Leveque, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 401 - 401
  • [4] Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1.
    Garon, Edward B.
    Schneider, Jeffrey Gary
    Wong, Deborah J. L.
    Aljumaily, Raid
    Korn, Wolfgang Michael
    Infante, Jeffrey R.
    Patel, Manish R.
    Autio, Karen A.
    Papadopoulos, Kyriakos P.
    Naing, Aung
    Gabrail, Nashat Y.
    Munster, Pamela N.
    Goldman, Jonathan Wade
    Hung, Annie
    Van Vlasselaer, Peter
    Leveque, Joseph
    Oft, Martin
    Spigel, David R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors
    Garon, E. B.
    Wong, D. J.
    Schneider, J. G.
    Aljumaily, R.
    Korn, W. M.
    Patel, M. R.
    Autio, K. A.
    Papadopoulos, K. P.
    Naing, A.
    Gabrail, N.
    Munster, P. N.
    Goldman, J.
    Hung, A.
    Oft, M.
    Leveque, J.
    Spigel, D. R.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 407 - 407
  • [6] Seasonal variation in effect of anti-PD-1 initiation on overall survival among patients with advanced melanoma
    Ellebaek, Eva
    Schina, Aimilia
    Schmidt, Henrik
    Haslund, Charlotte Aaquist
    Bastholt, Lars
    Svane, Inge Marie
    Donia, Marco
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2023, 36 (02) : 224 - 231
  • [7] PROGNOSTIC FACTORS FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED MELANOMA TREATED WITH ANTI-PD-1 THERAPY - THE MELIMMUNE SCORE
    Lobo-Martins, Soraia
    Martins-Branco, Diogo
    Semedo, Patricia Miguel
    Alvim, Cecilia Melo
    Monteiro, Ana Maria
    Vendrell, Ines
    Gouveia, Emanuel
    Passos, Maria Jose
    Costa, Luis
    Mansinho, Andre
    de Sousa, Rita Teixeira
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A4 - A4
  • [8] Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
    Hamid, Omid
    Robert, Caroline
    Daud, Adil
    Hodi, F. Stephen
    Hwu, Wen-Jen
    Kefford, Richard
    Wolchok, Jedd D.
    Hersey, Peter
    Joseph, Richard W.
    Weber, Jeffrey S.
    Dronca, Roxana
    Gangadhar, Tara C.
    Patnaik, Amita
    Zarour, Hassane
    Joshua, Anthony M.
    Gergich, Kevin
    Elassaiss-Schaap, Jeroen
    Algazi, Alain
    Mateus, Christine
    Boasberg, Peter
    Tumeh, Paul C.
    Chmielowski, Bartosz
    Ebbinghaus, Scot W.
    Li, Xiaoyun Nicole
    Kang, S. Peter
    Ribas, Antoni
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02): : 134 - 144
  • [9] S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
    Wagner, Nikolaus B.
    Forschner, Andrea
    Leiter, Ulrike
    Garbe, Claus
    Eigentler, Thomas K.
    [J]. BRITISH JOURNAL OF CANCER, 2018, 119 (03) : 339 - 346
  • [10] S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
    Nikolaus B Wagner
    Andrea Forschner
    Ulrike Leiter
    Claus Garbe
    Thomas K Eigentler
    [J]. British Journal of Cancer, 2018, 119 : 339 - 346
12345